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Background: The genetic diversity of loci and mutations underlying hereditary hearing loss is an active area of
investigation. To identify loci associated with predominantly non-syndromic sensorineural hearing loss, we
performed exome sequencing of families and of single probands, as well as copy number variation (CNV) mapping
in a case–control cohort.
Results: Analysis of three distinct families revealed several candidate loci in two families and a single strong
candidate gene, MYH7B, for hearing loss in one family. MYH7B encodes a Type II myosin, consistent with a role for
cytoskeletal proteins in hearing. High-resolution genome-wide CNV analysis of 150 cases and 157 controls revealed
deletions in genes known to be involved in hearing (e.g. GJB6, OTOA, and STRC, encoding connexin 30, otoancorin,
and stereocilin, respectively), supporting CNV contributions to hearing loss phenotypes. Additionally, a novel region
on chromosome 16 containing part of the PDXDC1 gene was found to be frequently deleted in hearing loss
patients (OR = 3.91, 95% CI: 1.62-9.40, p = 1.45 × 10−7).
Conclusions: We conclude that many known as well as novel loci and distinct types of mutations not typically
tested in clinical settings can contribute to the etiology of hearing loss. Our study also demonstrates the challenges
of exome sequencing and genome-wide CNV mapping for direct clinical application, and illustrates the need for
functional and clinical follow-up as well as curated open-access databases.
Keywords: Hereditary Hearing Loss, MYH7B, Exome sequencing, Copy number variation, Array Comparative
Genome Hybridization (aCGH)Background
Hereditary sensorineural hearing loss (SNHL) is a highly
prevalent disorder in humans, affecting 1 in 500 newborns
[1]. There is considerable genetic heterogeneity underlying
SNHL. Approximately 133 autosomal non-syndromic loci
(55 dominant and 78 recessive) have been mapped, and
within these, 78 genes are causally implicated in non-
syndromic hearing loss: 30 for dominant and 48 for
recessive hearing loss. In addition, there are three non-
syndromic X-linked genes known to date (http://heredi-
taryhearingloss.org, accessed February 24, 2014). Despite* Correspondence: mpsnyder@stanford.edu
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unless otherwise stated.the large number of implicated loci only one region has
been shown to be a major etiological contributor to
bilateral autosomal recessive non-syndromic hearing loss
(ARNSHL). The DFNB1A/B locus contains the GJB2 and
GJB6 genes, which encode the connexin 26 and connexin
30 proteins, respectively, and GJB2 has been shown to be
frequently mutated in individuals with severe ARNSHL
[2,3]. Because the region responsible for many of the
remaining cases has not been identified there are likely to
be other yet-to-be-discovered genetic contributors that
may underlie a significant proportion of cases.
Most SNHL loci have been discovered using homozy-
gosity mapping and other forms of linkage analysis in
large consanguineous families [4]. There have been few
genome-wide association studies on SNHL [5,6], andtral. This is an Open Access article distributed under the terms of the Creative
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(http://deafnessvariationdatabase.com). Only one study
has investigated the effects of copy number variants (CNVs)
on SNHL in a comprehensive, though low-resolution
fashion. This study found only one CNV, a deletion of the
stereocilin gene STRC, that was associated with SNHL [6].
However, CNVs are enriched in genes involved in sensory
perception of the environment [7] including smell and taste
receptors [8]. Thus, there is a need to investigate the effects
of CNV on SNHL in a high-resolution, unbiased, genome-
wide manner, and further to investigate the integrated
effects of multiple types of variants on this phenotype [9].
The advent of high-resolution, genome-wide variant
mapping technologies, such as whole genome and ex-
ome sequencing, and microarray-based methods, now
allows unbiased detection of the entire spectrum of gen-
etic variants, including SNVs, indels, and CNVs, in indi-
vidual genomes [10-14]. Exome sequencing studies have
identified novel SNHL genes and/or mutations in pro-
bands, often followed by confirmation through limited
analyses of other family members [9,15-20].
In this study, we explored the utility of diverse and
complementary high-resolution approaches to detect
genetic variants associated with SNHL. We used mul-
tiple whole genome variant-mapping technologies, in-
cluding exome sequencing and high-resolution array
comparative genomic hybridization (aCGH), as well as
familial and association strategies, to determine indi-
vidually rare and frequent genetic contributors to SNHL
in three families and in over 150 individual probands,
for whom no conclusive genetic etiology had previously
been established. We report the discovery of rare com-
pound heterozygous mutations in the myosin heavy
chain 7B gene, MYH7B, as a novel likely cause of SNHL,
by exome sequencing a family of five individuals. We
also report several individually rare, novel candidate mu-
tations for SNHL, revealed by exome sequencing of two
additional families (of four and five individuals, respect-
ively) and 13 unrelated probands. Finally, we conducted
the first high-resolution, genome-wide CNV investiga-
tion for hearing loss. We report several novel CNV asso-
ciations found in a cohort of 150 affected individuals
and 157 controls, including a deletion on chromosome
16 encompassing the PDXDC1 gene, the has-mir-1972
micro RNA, and part of the NPIP. These results support
our hypothesis that SNHL may manifest due to either
underlying shared or individually rare genetic etiologies
in different cases, and arise by multiple mechanisms.
Results
Two strategies to investigate novel genetic contributors
to SNHL
We used two strategies to investigate the genetic varia-
tions underlying SNHL in individuals for whom noprevious genetic etiology had been established. The first
strategy involved analyzing novel SNV and indel associa-
tions with SNHL using exome sequencing in three
affected families and 13 additional isolated probands
(Table 1). The second approach involved analyzing gen-
ome-wide copy number changes using high-resolution
aCGH to discover CNVs associated with SNHL in a
cohort of 150 probands and 157 controls (Table 2). This
cohort includes the 13 isolated probands from the exome
sequencing study. This multiple strategy approach was de-
signed to provide a detailed, yet comprehensive investiga-
tion of the type and nature of mutations affecting hearing.
Exome sequencing of individuals with familial and
sporadic hearing loss
We performed exome sequencing on three families with
different levels of sensorineural hearing loss. The severity
of the hearing loss was determined by behavioral pure
tone audiometry. Family 1 is of middle-eastern descent
and afflicted with severe-profound bilateral hearing
loss (>90 dB) and megalocornea with secondary glau-
coma. Family 2 is of European-Caucasian descent and
afflicted with moderate hearing loss (~50 dB). Family 3
of European-Caucasian descent has mild hearing loss
(~40 dB) (Figure 1). We also performed exome sequen-
cing on 13 additional probands and searched for rare,
highly penetrant SNVs and indels that may explain the
phenotype. In each case we aligned 100 bp paired-end
sequencing reads and called SNVs and indels using the
Nucleotide-level Variation tool from DNAnexus. For
the three families we also independently aligned reads
and called SNVs and indels using the Variant 1.0 algo-
rithm from Real Time Genomics (RTG) (Figure 2a). We
note that the total number of variants called per genome
differ significantly between the two algorithms due to
technical differences. DNAnexus calls variants individually
in each genome and then we used family structure to
apply various segregation models. RTG uses the familial
structure a priori to call variants segregating in the family
under various inheritance models (see Methods). We then
used Ingenuity Variant Analysis (IVA) to filter the variants
based on quality, frequency in known populations, pre-
dicted deleteriousness, genetic analysis (families only) and
biological context (Figure 2b). We discovered multiple
potential genetic etiologies in the studied families and in
the individual probands.
Compound heterozygous missense mutations in MYH7B are
the likely cause of hearing loss in family 1
Family 1 has a severe hearing defect that segregates in a
recessive manner (Figure 1a). The exomes of the two
unaffected parents and three affected children were
analyzed as described above. Of the 88,975 and 346,430
variants called by RTG and DNAnexus, respectively,
Table 1 Exome sequencing study subjects
Study
number
Sex Ethnicity Age of onset Level and type of
hearing loss
Condition Family history Other findings Sequence variation
1 M Mexican Congenital Bilateral profound,
sensorineural





Unknown Negative None GJB2: negative
3 F East Asian Age 9 High frequency
sensorineural hearing loss,
left more severe
Unknown Negative None GJB2 and GJB6: negative; SLC26A4:
heterozygous for c.463 A > G,
p.Met155Val (a novel variant of
uncertain pathogenic significance)
4 M Mexican Congenital Bilateral profound,
sensorineural
Stable Similarly affected sibling None GJB2 and GJB6: negative
5 M Caucasian Age 2 Bilateral mild to
moderate, sensorineural
Progressive Mother with bilateral severe hearing
loss, recognized around age 16
None GJB2: negative
6 F Caucasian Congenital L - profound, R - moder-
ate, sensorineural
Stable Similarly affected sibling None GJB2: negative
7 M Mexican Congenital Bilateral severe to
profound, sensorineural
Stable Negative None GJB2: negative
8 F Caucasian-
East Asian
Age 1 L- severe, R - profound,
sensorineural




Congenital L - moderate, mixed hear-
ing loss, R - moderate,
sensorineural
Stable Negative None GJB2: negative
10 M Mexican Congenital Bilateral moderate,
sensorineural
Stable Hearing of unknown etiology loss on
paternal side
None GJB2, SLC26A4: negative
11 F Mexican Congenital Bilateral moderate,
sensorineural
Stable Negative None GJB2: negative
12 M Caucasian Congenital Bilateral moderate,
sensorineural
Stable Negative None GJB2: negative
13 M East Asian After age 7,
confirmed at age 14
Bilateral profound,
sensorineural
Progressive Negative None GJB2: heterozygous for c.11G > A,




N/A N/A Unaffected Affected offspring None; consanguineous
F1.2 F Middle
Eastern
N/A N/A Unaffected Affected offspring None; consanguineous
F1.3 M Middle
Eastern
Congenital Bilateral severe to
profound, sensorineural




GJB2 and GJB6: negative
F1.4 M Middle
Eastern
Congenital Bilateral severe to
profound, sensorineural





















Table 1 Exome sequencing study subjects (Continued)
F1.5 F Middle
Eastern
Congenital Bilateral severe to
profound, sensorineural
Progressive Similarly affected siblings Megalocornea with
secondary glaucoma
F2.1 M Caucasian N/A N/A Unaffected Affected offspring None, normal
chromosomes
F2.2 F Caucasian N/A N/A Unaffected Affected offspring None, normal
chromosomes
F2.3 F Caucasian Congenital Bilateral moderate,
sensorineural
Stable Proband with similarly affected
identical twin
None GJB2, GJB6, mitochondrial
mutation panel: negative
F2.4 F Caucasian Congenital Bilateral moderate,
sensorineural
Stable Similarly affected identical twin None GJB2, GJB6, mitochondrial
mutation panel: negative
F2.5 M Caucasian Congenital Bilateral moderate,
sensorineural





F3.1 M Caucasian N/A N/A Unaffected Affected offspring None
F3.2 F Caucasian Unknown Mild Unknown Affected offspring, affected mother Mother reported to have
a white forelock
F3.3 M Caucasian Failed initial newborn
screening but passed
a rescreen. At age 3 mild
to moderate hearing loss
was identified
Bilateral mild to moderate Progressive Proband with similarly affected sibling,
mildly affected mother and maternal
grandmother
None GJB2, GJB6, SLC26A4: negative
F3.4 M Caucasian Congenital Bilateral mild to moderate Progressive Similarly affected sibling, mildly
affected mother and maternal
grandmother
None




















Figure 1 Families affected with syndromic hereditary hearing loss. Filled symbols indicate individuals affected with hearing loss. Audiograms
are representative of the hearing loss in all affected members of each respective family. a. Family 1 showing Mendelian recessive inheritance of
severe to profound hearing loss. The audiogram corresponds to proband F1.5. b. Family 2 showing Mendelian recessive inheritance of moderate
hearing loss or dominant de novo inheritance in the twins. The audiogram corresponds to proband F2.4. c. Family 3 showing Mendelian
dominant inheritance of mild hearing loss. The audiogram corresponds to proband F3.3.
Table 2 CNV association study samples
Phenotype Total Gender Ethnicity












Affected 150 65 85 44 59 27 6 4 6 4 0
Unaffected 157 79 78 132 16 5 0 2 0 2 1
Affected individuals were recruited at Stanford University under IRB approval. Unaffected individuals matched for sex, age, and ethnicity were collected under IRB
approval at Stanford University (n = 31), Mount Sinai University (n = 88) and Yale University (n = 38) using identical selection criteria. Ethnicity was determined
using Principal Components Analysis with the Human Genome Diversity Panel.
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Figure 2 Exome sequencing analysis and variant filtering scheme. a. Analysis protocol for exome sequencing study. b. Variant filtering
scheme using Ingenuity Variant Analysis (IVA) for variant prioritization of exome data.
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276,015, respectively, had a call quality of at least 20 in
all samples. Variants with an allele frequency of 3% or
greater in the genomes of the 1000 genomes project, the
public Complete Genomics genomes, or the NHLBI ESP
exomes (collectively referred to as public genomes here-
after), were excluded, leaving 17,249 variants for RTG
and 85,007 for DNAnexus. 6,312 and 9,618 of the RTG
and DNAnexus variants, respectively, were experimen-
tally observed or predicted to be damaging by IVA. Fur-
ther filtering based on segregation in a recessive fashion
yielded six SNP/indel (RTG) and three SNP (DNAnexus)
variants. These independent analyses had only two vari-
ants in common. They were both heterozygous missense
mutations in the MYH7B gene on chromosome 20q11.22.
Relaxing the rarity filter to encompass variants that oc-
curred at a frequency ≤ 15% in the public genomes did not
yield any additional candidates.
One of the two MYH7B variants (v1: p.Arg1693Gln)
is heterozygous in the father and the other (v2: p.
Asp557Asn) is heterozygous in the mother (Figure 3a).
Each parent carries only one mutant allele but all three
affected children are compound heterozygous for both
mutations (Figure 3b). The maternal variant was present
in dbSNP (Build 137) and present in the 1000 Genomes
Project and Exome Sequencing Project samples at a fre-
quency of 0.05% and 0.01%, respectively. The paternal
variant was not present in dbSNP, the 1000 Genomes
Project, or the Exome Sequencing Project samples.
Neither variant was present in any of the other exomes
of probands in our cohort. Thus, both variants appear to
be rare and the paternal variant may be private to this
family. We further analyzed these mutations using theCombined Annotation Dependent Depletion algorithm
(CADD), a general framework for estimating the relative
pathogenicity of genetic variants in humans [21]. They
received scaled C scores of 27 and 33 for v1 and v2,
respectively, indicating that these variants are in the 0.2
and 0.05 percentile of most deleterious substitutions in
the human genome, respectively (Figure 3c). These vari-
ants were verified by Sanger sequencing in all family
members (Figure 3d).
MYH7B encodes a heavy chain of myosin II, a member
of the motor-domain superfamily. The myosin II mol-
ecule is a multi-subunit complex made up of two heavy
chains and four light chains. The heavy chain comprises
a catalytic globular motor domain, which carries out
ATP hydrolysis and interacts with actin, and a tail domain
in which heptad repeat sequences promote dimerization
by interacting to form a rod-like alpha-helical coiled coil.
The maternal variant lies in the relay loop of the catalytic
motor domain and the paternal variant is located in
the tail domain, which is responsible for dimerization
(Figure 3a). The MYH7B gene has not been previously
implicated in hearing loss but has been linked to
differentiation of inner ear hair cells [22] and shown to
control actin networks within neurons [23].
MYH7B is expressed in the inner ear
We next examined expression of the MYH7B gene in
the literature and in the Allen Brain Atlas. MYH7B was
found to be concordantly expressed in embryonic mouse
inner ear tissue but not in non-inner ear tissue, with
atonal homolog 1a, ATOH1, a gene required for hair cell
differentiation [22]. This concordant expression likely in-
dicates a role for MYH7B in development of hair cells in
Figure 3 Compound heterozygous mutations in the MYH7B gene segregate with the hearing loss in Family 1. a. MYH7B protein showing
functional domains and locations of missense mutations in the paternal and maternal alleles. b. Segregation of heterozygous missense mutations
in the MYH7B gene in Family 1. c. Description and population frequencies of rare paternal and maternal alleles of MYH7B. d. Verification of
compound heterozygous mutations in proband F1.3 by Sanger sequencing. These data are representative of those of the other family members.
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Allen Brain Atlas indicates high MYH7B expression in
the primary auditory cortex and regions of the auditory
pathway such as the cochlear nuclei and inferior collicu-
lus, in adult humans [24]. Furthermore, a reduction in
MYH7B expression in cultured mature rat hippocampal
neurons can cause profound alterations to dendritic
spine morphology, excitatory synaptic strength, and the
actin cytoskeleton [23]. It is possible that these effects
may extend to other neuronal tissues including the audi-
tory complex.
Variant filtering results in a shortlist of potential causative
mutations underlying the hearing loss in families 2 and 3
The hearing loss in family 2 is moderate and bilateral
and appears to segregate in either a recessive or domin-
ant de novo fashion in female twin offspring (Figure 1b).
An additional male sibling has multiple congenital
abnormalities, including hearing loss, which can be
explained by chromosomal abnormalities that are absent
in the twins. Accordingly, his hearing loss is different
from that in the twins as confirmed by audiogram (not
shown) and he was excluded from the analysis of this
family. The exomes of the other four family members
were analyzed as above. In this family, 469,864 variants
were called in total, either by RTG (94,974 total), DNA-
nexus (438,031 total), or both (63,141). Filtering was per-
formed using IVA on the union set of variants called byboth algorithms to maximize findings. After removing
common variants and low quality calls, two genetic
models were applied; dominant de novo and recessive
inheritance. We searched for dominant de novo muta-
tions that were called by both RTG and DNAnexus that
occurred in both twins. No such mutations were found.
However, two potential candidates were found by DNA-
nexus only. These were a heterozygous in-frame dele-
tion, (p.Ala23-Leu25del), in the CTBS gene (encoding
Di-N-acetylchitobiase), and a heterozygous missense mu-
tation (p.Thr26Ala) in the RBMXL1 gene (encoding RNA
binding motif protein, X-linked-like 1) and in an intron of
the gene CCBL2 (encoding Cysteine Conjugate-Beta
Lyase 2). The search for underlying variants following a
recessive pattern of inheritance did not generate any
robust candidates.
Family 3 is characterized by mild to moderate bilateral
hearing loss appearing to segregate in an autosomal
dominant fashion (Figure 1c). However, the level of
hearing loss in the mother is milder than that of the
children. This indicates either incomplete penetrance of
the causative allele that is segregating in an autosomal
dominant manner, or compounding of the phenotype
due to the additive effects of some putative paternal
variant along with the maternal variant. It is also pos-
sible that the hearing loss in the mother is different from
that in the children. However, this scenario is less likely
given the seemingly Mendelian inheritance.
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as above. In total, 327,843 variants were called either by
RTG (91,397 total), DNAnexus (293,696 total), or both
(57,250). Filtering was performed in IVA on the union
set of variants called by both algorithms. After removing
common variants and low quality calls, only 14 variants
were called by both RTG and DNAnexus, were predicted
to be deleterious by IVA, and segregated in an auto-
somal dominant manner (Table 3). All but one of these
has been reported in dbSNP. In this set, seven missense
mutations were found, of which four were predicted to
be damaging and three were predicted to be activating
by SIFT. Five of these were heterozygous in all affected
individuals while two were homozygous in the affected
mother and heterozygous in the children. Of these seven
variants, six occur in biological pathways at most two
nodes away from some gene known to be involved in
autosomal dominant non-syndromic hearing loss. These
six missense variants located in networks containing
known hearing loss genes (missense variants in Table 3
except the GAL3ST2 mutation) are the present leading
causative candidate mutations in this family.
Exome sequencing of individual probands reveals rare
deleterious mutations in genes known to be associated with
hearing loss
It is unknown how often sequencing of individuals with
hearing loss will identify likely underlying causes of the
disease. We therefore also sequenced the exomes of 13
individual probands for which additional family mem-
bers were not available. We used DNAnexus Nucleotide-
Level Variation Analysis to detect SNPs and indels in each
proband. Between 114,135 and 228,298 variants were
found in each exome (mean = 188,659 variants per ex-
ome). Using the IVA variant filtering scheme described in
the methods and published at https://variants.ingenuity.
com/Haraksingh-etal-2013-HHLa, 21,554 potentially dele-
terious variants in 9,715 genes were revealed in this set of
probands. Of these 133 variants occurred in 46 genes that
have previously been associated with hearing loss. Be-
tween 12–23 predicted deleterious variants (mean = 17)
located in 10–21 genes (mean = 13) known to be asso-
ciated with hearing loss were found in each proband
(Figure 4). In each proband, between one and six known
hearing loss genes (mean = 3) with more than one predicted
deleterious mutation were found.
In five of the 13 probands likely causative mutations
can be identified. These are rare homozygous variants
that are predicted to be damaging in known hearing loss
genes. Proband 2 carries a stop loss in the MYO7A gene
(p.*1179Gly) and a missense mutation (p.Pro426Leu) in
the MYO1A gene. Proband 3 has a missense mutation
(p.Leu2886Phe) in the USH2A gene that has been previ-
ously associated with Usher Syndrome in a Spanishfamily. There is a rare in-frame variant (p.398delGln) in
the TRIOBP gene in probands 7 and 13, and proband 13
carries a missense mutation (p.Met6159Val) in the
GPR98 gene. Proband 9 carries a missense mutation
(p.Lys130Glu) in the USH1G gene. These damaging
homozygous mutations are the strongest candidates for
causing hearing loss in the five associated probands.
Retinal abnormalities had not been observed in the two
probands with mutations in Usher syndrome genes, but
both were young children.
Seven of the remaining eight probands carry at least
one rare homozygous variant in genes one node away
from a known hearing loss gene in Ingenuity-curated
biological pathways. These variants were not found in
the unaffected family members from our cohort. These
rare, homozygous, deleterious variants represent the
most likely causative alleles in these probands. The vari-
ants can be viewed at https://variants.ingenuity.com/
Haraksingh-etal-2013-HHLb by invoking the ‘Homozy-
gous’ filter followed by the ‘Hearing-relevant’ filter after
the ‘Rarity’ filter.
Additionally, many genes were found containing recur-
rent predicted deleterious variants in at least two pro-
bands of our cohort. For example, under a dominant
model, 398 genes contained recurrent variants in more
than two probands and not in the unaffected members
of families 1, 2, or 3. These genes may represent add-
itional recurrent candidates underlying the hearing loss
in our set of probands. The results of this analysis and
other adjustments to the genetic model can be explored
at https://variants.ingenuity.com/Haraksingh-etal-2013-
HHLb. The dominant analysis results are obtained by
moving the ‘Homozygous’ and ‘Hearing-relevant’ filters
to the bottom of the cascade.
Overall, these results indicate that strong candidates
can often be found by exome sequencing of genomic
DNA of hearing loss patients. In other cases, larger
numbers of candidates can be identified, the meaning of
which is more difficult to distil.
Genome-wide CNV mapping reveals several CNVs
associated with SNHL
In our second approach, we carried out a high-resolution,
genome-wide CNV association study of SNHL using 150
affected individuals, including the 13 isolated probands
whose exomes were sequenced, and 157 controls. We
mapped CNVs by aCGH on the NimbleGen 2.1 M CNV
array, the most sensitive array-based CNV detection plat-
form available at the time [13]. We then called CNVs
using two algorithms, Nexus Copy Number 6 (Biodiscov-
ery) and NimbleScan 2.6 (NimbleGen). Association testing
was performed for genomic regions affected by CNVs
including single loci, genes, and pathways, as well as
for overall CNV load. We found an associated deletion












frequency (v3)F3.2 F3.3 F3.4
1 908929 C T Exonic PLEKHN1 c.1238C > T; c.1343C > T p.S413L; p.S448L het het het missense 142080242 0.27
1 3440753 G A Exonic MEGF6 c.539C > T p.P180L het het het missense 41307039 0.51
1 15546259 G A 3'UTR TMEM51 c.*20G > A het het het 199958353
1 68649258 C T Intronic; microRNA WLS;mir-1262 c.373 + 10380G > A;
c.107-24328G > A; c.379 +
10380G > A
het het het 147113488 0.65
1 234742618 G A 3'UTR IRF2BP2 c.*265C > T het het het 192276553 0.33
1 245772651 C G Exonic KIF26B c.1735C > G p.L579V hom het het missense 61754955 2.5
2 68546588 C A 5'UTR CNRIP1 c.-56G > T het het het 185949133 2.35
2 86439256 A T Intronic; 3'UTR MRPL35 c.513-293A > T;
c.*1465A > T
het het het 192903152 0.14
2 97531651 G A Exonic SEMA4C c.274C > T p.P92S het het het missense 141610691
2 99978074 A T Exonic EIF5B c.710A > T p.E237V het het het missense 201583340
2 109087823 AAA Exonic; ncRNA GCC2 c.2038_2040delAAA p.680delK het het het in-frame
2 111875388 C T Exonic ACOXL c.1738C > T p.L580F hom het het missense 193151657 0.7
2 233630577 G A 3'UTR; Intronic GIGYF2; KCNJ13 c.*2324C > T; c.532 +
4431G > A; c.*2886C > T
het het het 74547374 0.65
2 242742842 A G Exonic GAL3ST2 c.458A > G p.Y153C het het het missense 139344622 0.05
Family 3 variants with quality >20, frequency in the public genomes < 3%, called by both RTG and IVA as predicted deleterious, and showing dominant inheritance patterns. The chromosomal locations, gene regions,
gene symbols, transcript variants, protein variants, genotype, translation impact, dbSNP identifier, and 1000 Genomes Project frequency are shown.




















Figure 4 Predicted deleterious variant load in known SNHL genes derived from exome sequencing of SNHL probands. Black lines
demarcate families. Purple bars indicate unaffected parents of probands in families. All included variants had a call quality greater than 20, and a
frequency less than or equal to 15% in the 1000 genomes project, ESP, and Complete Genomics. The data represents a total of 134 variants in 46
genes (exons, splice sites, and miRNAs only).
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(OR = 3.91, 95% CI: 1.62-9.40, p = 1.45 × 10−7) as well
as other less significant CNV associations. Additionally,
we performed SNP genotyping of 150 cases and 28 con-
trols using the Illumina 1 M SNP array and carried out
a genome-wide association study (GWAS) using our cases
and a large set of publicly available controls. Finally, we
investigated whether there were combined effects of SNV
and indel mutations with CNVs in the same locus for the
13 individual probands. The latter two approaches did not
yield significant results.
In total, 155,634 CNVs were called by Nexus (12,555
total, 6,282 unique in cases and 143,079 total, 93,446
unique in controls), and 310,753 CNVs were called by
NimbleScan (146,223 total, 34,939 unique in cases and
164,530 total, 37,202 unique in controls). We define a
unique CNV call as one that contains a unique pair of
start and end coordinates. 1,726 and 20,510 unique
CNVs were common to both the case and control
groups as called by Nexus and NimbleScan respectively.
Between two and 6,172 CNVs were called by Nexus
(median = 89), and between 394 and 1,731 were called
by NimbleScan (median = 1,036.5) in the individual
genomes (Additional file 1: Figure S1). It was found that
the individual cases and controls have similar genome-
wide CNV loads. (However, note that a handful of out-
liers in the control group showed hundreds more NexusCNV calls than the rest of the cohort). The Nexus CNV
calls tend to be much larger for the cases than the con-
trols. There is an enrichment of CNV calls between 30–
80 kb in the cases, as well as a higher relative frequency
of Nexus CNV calls that are greater than 100 kb. The
NimbleScan case and control CNV calls are generally
similar in size (Additional file 2: Figure S2).
CNVs were tested for association with the phenotype
using the Classic calculation option of the Comparisons
function in Nexus 6.0. Smallest regions of overlap of the
individual CNVs were used. The most significant associ-
ation is an approximately 72.5 kb (smallest region of over-
lap) deletion on chromosome 16 (hg18; chr16:14,956,245-
15,028,783) encompassing the first 15 exons of the
PDXDC1 gene, the has-mir-1972 micro RNA, and the
intergenic region between PDXDC1 and the upstream
NPIP gene (Figure 5a). Some of the individual deletions
extend far enough upstream to include the NPIP gene as
well as the five 3’ most exons of the NOMO1 gene which
is further upstream. This region was previously reported
in the Database of Genomic Variants (DGV) and is
thought to be the result of a duplication expansion in the
human genome. The smallest region of overlap of the
deletions is called in 23 cases and 7 controls by both algo-
rithms independently producing an odds ratio of 3.91
(95% CI: 1.62-9.40, p = 1.45 × 10−7). An additional 17 sub-
jects and eight controls carry the deletion as called by a
Figure 5 Chromosome 16p13.11 deletion associated with SNHL. a. The frequencies of the deletion on chromosome 16 encompassing part
of the PDXDC1 gene are indicated for the entire sample set, as well as separated out for the affected individuals and controls (highlighted in the
black box). Green shading indicates duplications whereas red shading indicates deletions. The horizontal tracks indicate the coordinates of the
position along chromosome 16p13.11 (hg18). Gene and exon tracks are included. b. The frequencies of the deletion among the various ethnic
groups; African, Caucasian, East Asian, Mexican, and Native American. Frequencies were calculated separately for CNVs called by both algorithms
and for CNVs called by one algorithm (Nexus) only.
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algorithm, indicates that the deletion is present in 40 af-
fected individuals and 15 controls producing an odds ratio
of 3.47 (95% CI: 1.82-6.60). The deletion is present in the
same number of Mexican cases and controls but signifi-
cantly more East Asian (12 versus two) and Caucasian
(five versus two) cases than controls when considering
cases where both algorithms called the CNV (Figure 5b).
We observed deletions encompassing the entire STRC
gene in seven cases and two controls as called by both
algorithms, and in an additional control called by just
the NimbleScan algorithm. The deletions ranged in size
from 70–239 kb with the smallest region of overlap be-
ing hg18; chr15:41,639,153-41,709,787. This is the only
CNV that has previously been reported to be associated
with mild to moderate hearing impairment in GJB2 mu-
tation negative probands [6].
Each gene in the NCBI Reference Sequence Database
(RefSeq), including 10 kb up and downstream of thegene, was tested for association with the phenotype
under the premise that different mutations in the same
gene can lead to the phenotype. The frequency at which
each gene overlapped a CNV by at least one base pair
was calculated for the cases and controls. A Fisher’s
Exact Test was performed to determine whether the fre-
quency differences between the cases and controls were
significant. Associations that either contained the lowest
p-values (before Bonferroni correction, which is fre-
quently too stringent for GWAS studies) with the case
frequency being higher than the control frequency, the
lowest control frequency, or the most consistent trend
from both CNV calling algorithms were the most func-
tionally promising (Table 4). As expected, the three
genes in the deletion on chromosome 16 (NOMO1,
NPIP and PDXDC1) found to be associated were among
the top candidates in this second set of association tests.
Additionally, the OTOA gene, known to be associated
with SNHL [1], was found to be significantly associated
Table 4 Interesting genes significantly associated with SNHL
Gene Nexus NimbleScan
Case frequency Control frequency OR 95% CI FET p-value Case frequency Control frequency OR 95% CI FET p-value
NOMO1 41 13 4.20 9 4 2.46
2.14-8.21 0.74-8.16
1.88E-05 1.63E-01
GRAPL 68 38 2.62 43 27 1.95
1.61-4.26 1.13-3.36
1.26E-04 2.09E-02
PDXDC1 41 16 3.33 24 9 3.15
1.78-6.26 1.41-7.03
1.27E-04 5.17E-03
FCGR2C 45 23 2.51 14 9 1.70
1.43-4.42 0.71-4.06
1.54E-03 2.81E-01
NBPF4 18 6 3.45 1 1 1.05
1.33-8.96 0.07-17.00
9.96E-03 1.00E + 00
NPIP 44 28 1.92 41 17 3.12
1.12-3.30 1.68-5.79
2.21E-02 2.56E-04
FAM115A 45 29 1.91 23 16 1.6
1.12-3.25 0.81-3.18
2.34E-02 2.30E-01
OTOA 18 8 2.56 5 1 5.13
1.08-6.07 0.59-44.47
3.97E-02 1.15E-01
Functionally interesting genes containing CNVs showing statistically significant associations with SNHL. The genes, case and control frequencies using both CNV
calling algorithms, odds ratios, 95% confidence intervals, and p-values derived from Fisher’s Exact Tests are listed.
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ated as well. This gene has no known function, but it is
one of five genes that lies within the region of overlap of
two previously discovered deafness associated genomic
regions, DFNB82 and DFNB32 [15].
In order to test the hypothesis that different individ-
uals may carry distinct mutations in a particular pathway
which all result in the same phenotype, we carried out
pathway association tests. Each pathway in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) containing
a gene previously known to be associated with hearing
loss was tested for association in this cohort. A Fisher’s
Exact Test was used to determine if particular pathways
were significantly enriched for CNVs in the cases versus
the controls. No such pathway was found.
Finally, the CNV load in the cases versus controls of
the set of 46 genes known to be associated with SNHL
was tested. There was no significant difference in CNV
load in the cases versus the controls for this set of genes.Combined effects of CNVs and point mutations in the
DFNB1 locus may explain the hearing loss in several
probands
Deletions of the DFNB1 locus at chromosome 13q11-
q12 have been described previously but are uncommon
in most populations. This locus includes GJB2 and GJB6
encoding connexin 26 and connexin 30, respectively, the
two main connexins expressed in the cochlea. To date,
four recessive GJB6 mutations have been reported [25-32].
The two most common are del(GJB6-D13S1830) and del
(GJB6-D13S1854), which truncate GJB6 and affect expres-
sion levels of the GJB2 gene [33,34]. The other two are
private. One deletes both GJB2 and GJB6 [31] and the other
(del(chr13:19,837,343-19,968,698) lies upstream from the
GJB6 gene and does not affect either gene directly [30,32].
In our study, we discovered two probands with hetero-
zygous ~232 kb del(GJB6-D13S1854) deletions in the
DFNB1 locus encompassing parts of the GJB6 and
CRYL1 genes and the putative regulatory region of the
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gous deleterious point mutations in the GJB2 gene as
discovered by the APEX array and Sanger sequencing;
the missense p.Gln80Pro and frameshift g.35delG muta-
tions respectively. Although we cannot determine from
our data whether the deletion and point mutations occur
in cis- or trans- configurations, it is likely that the com-
pounded effects of a point mutation in GJB2 and a
deletion of its putative regulatory elements explain the
hearing loss in these probands. Our cohort also con-
tained one proband and one control who were carriers
of a previously identified heterozygous ~309 kb del
(GJB6-D13S1830) deletion, which was confirmed by our
CNV analysis.
Additionally, we discovered a novel smaller heterozy-
gous deletion (~2-4 kb) in the DFNB1 locus that was
called by at least one algorithm in 19 affected individuals
and 40 controls. This deletion is ~60 kb upstream of the
GJB6 gene and does not overlap any other genes. Of the
19 cases with this deletion, nine carried an additional
known heterozygous deleterious mutation in GJB2 that
was determined by the arrayed primer extension (APEX)
array and Sanger sequencing. It is possible that this 2 kb
deletion may overlap regulatory elements of the GJB2 or
GJB6 genes. The combined effects of the deletion and
deleterious point mutations may explain the hearing loss
in these nine probands. The remaining cases may con-
tain unidentified deleterious mutations on the non-
deleted allele while the controls do not. Alternatively,
the 2–4 kb deletion may simply be a benign common
CNV. With the current data set, we cannot resolve these
possibilities.
Discussion
Using exome sequencing we have identified defects in a
myosin II gene, MYH7B, as the likely contributors to
hearing loss in one family. Although several other my-
osin heavy chain genes have been previously implicated
in hearing loss, the MYH7B gene has not. However,
there is indirect support for MYH7B involvement in
hearing including expression in embryonic mouse inner
ear tissue [22], expression in the primary auditory com-
plex in humans, and the control of dendritic spine
morphology, excitatory synaptic strength, and the actin
cytoskeleton in rat neurons [23]. This, along with the
segregation pattern, rarity, high quality, and location of
the variants in functional domains strongly suggest that
the predicted deleterious compound heterozygous muta-
tions in MYH7B cause the hearing loss in family 1. The
same sequence changes may also be responsible for the
megalocornea phenotype in this family as it has been
shown that MYH7B transcripts are present in extraocu-
lar muscles from human, rat, and mouse, and in devel-
oping mouse eye skeletal muscle [35,36]. Changes inextraocular muscle tension can produce significant
changes in corneal topography [37]. Interestingly, a sin-
gle proband in our CNV cohort was found to harbor a
deletion of the MYH7B gene, as called by Nexus. Our
results extend the role of cytoskeletal proteins in hearing
and offer the possibility that mutations in the MYH7B
gene may constitute a rare cause of hearing loss.
Exome sequencing of isolated probands revealed likely
causative variants for hearing loss in five cases. Interest-
ingly, two of these probands had two homozygous rare
mutations in known hearing loss genes. The rarity of
such an occurrence suggests that it is plausible that both
mutations may be required for hearing loss. For the
remaining probands, multiple homozygous mutations in
genes in hearing-relevant pathways and multiple hetero-
zygous deleterious mutations were present. It is possible
that hearing loss in these patients is due to rare deleteri-
ous homozygous mutations in novel hearing-associated
genes, or to codominant, compound heterozygous, or non-
allelic non-complementation of heterozygous mutations in
distinct genes previously not known to affect hearing. Des-
pite extensive variant filtering and prioritization we are still
left with unmanageable numbers of potentially causative
mutations in many probands, which we were unable to
further refine. Complete distillation of the extensive
findings of potentially causative mutations will require
expression database analysis (e.g. http://hereditaryhear-
ingloss.org/main.aspx?c=.HHH&n=86597), functional
assays in cell and animal models, meta-association ana-
lyses of integrated data from multiple genomic studies,
and development of novel methods for discerning com-
binatorial effects of variants.
To our knowledge, this is the first high-resolution
genome-wide CNV association study of hearing loss. We
discovered novel CNV associations in both known hear-
ing loss-associated genes and in novel candidates. Of
note, we found a strong association between a deletion
encompassing part of the PDXDC1 gene and hearing
loss. The function of this gene is unknown but it is
widely and highly expressed in the cerebral cortex, in-
cluding the primary auditory cortex, in newborn and
adult mice [38] (http://mouse.brain-map.org/experiment/
show?id=77869146). This work suggests a need to extend
the types of variants typically analyzed in diagnostic hear-
ing loss testing. Furthermore, we have shown the import-
ance of testing for multiple types of variants occurring in
combination in individual probands, such as known dele-
tions and point mutations in the DFNB1 locus. While
these heterozygous mutations do not individually explain
the phenotype, their compounded effects may well be
pathogenic.
Although we were unable to definitively identify the
causative SNHL variants for many probands in our co-
hort, we have found novel mutations that have credible
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taining accurate and comprehensive databases will be
paramount in driving progress in molecular hearing loss
diagnoses.
Conclusions
Our studies have revealed three important aspects of
identifying mutations associated with SNHL. First, ex-
ome sequencing of families can reveal novel mutations
segregating with SNHL, although not in every instance.
Second, exome sequencing of a small number of isolated
probands can reveal strong candidate hearing loss muta-
tions, although in some cases it remains challenging to
ascertain disease-causing mutations. Third, analysis of
CNVs can reveal novel mutations and loci associated
with hearing loss. By employing both familial and associ-
ation studies we have successfully identified rare and
potentially private as well as more frequent variants in
both novel and previously known candidate genes and
loci. Our results indicate that multiple strategies and
study designs will be necessary to fully resolve the entire
collection of mutations that underlie complex human
disorders such as hearing loss. We anticipate that future
advances in methods to determine the combinatorial
effects of mutations will enable effective assessment of
factors including long-range genetic interactions, and
will facilitate integrated association analyses of panels of
variants and specific phenotypes. At present however,
studies like this continue to reveal novel aspects of the




Informed consent, including consent to publish, was ob-
tained from all enrolled study subjects or their guardians
under Internal Review Board approved protocols from
Stanford University Medical Center. Controls were re-
cruited under informed consent, including consent to
publish, as part of Internal Review Board protocols at
Stanford University, Mount Sinai University, and Yale
University.
Sample selection
Exome sequencing study samples
The study included 13 probands who were diagnosed
with bilateral non-syndromic SNHL, ranging in severity
from mild to profound. In addition, the study encom-
passed parents and siblings of another three probands
with SNHL, for a total number of 27 study participants
(Table 1). The average age of the probands was four
years. Study subjects were enrolled at Stanford Univer-
sity under IRB approval. Prior to inclusion, the probands
were, at a minimum, tested for mutations in the GJB2gene by DNA sequencing, as part of their routine clin-
ical care. Probands were eligible for this study if this or
additional testing had identified no conclusive genetic
etiology for their hearing loss. Genomic DNA was iso-
lated from peripheral blood by standard methods. Muta-
tion analysis by APEX microarray identified or confirmed
sequence variants in 16 of the 18 probands (data not
shown)[39]. Individuals with environmental causes for the
hearing loss, which may include a history of trauma,
exposure to noise or ototoxic medications, intra-uterine
infection, and tumors or other conditions that can affect
hearing, were excluded. Individuals with a recognized
genetic syndrome were also excluded from this study.
CNV study samples
The 150 participating individuals were mostly children;
the average age was 10 years. These probands had bilat-
eral non-syndromic sensorineural hearing loss ranging
from mild to profound. They were recruited at Stanford
University under IRB approval. All probands were tested
for mutations in GJB2 prior to enrollment. Identical
selection criteria applied to the different study groups.
The set of 13 probands analyzed by whole exome
sequencing were included in the CNV analysis.
Genomic DNA was isolated from peripheral blood by
standard methods. Mutation analysis by an APEX micro-
array identified or confirmed sequence variants in 117 of
the probands (data not shown) and 44 of these were
additionally tested for mutations in the promoter and in
exon 1 of the GJB2 gene (data not shown). Controls for
these participants were matched unaffected individuals
of the same sex, age range (or older), and in the same
ethnic group to the extent possible. Controls were re-
cruited under informed consent as part of IRB protocols
at Stanford University (n = 31), Mount Sinai University
(n = 88), and Yale University (n = 38) (Table 2).
APEX microarrays
The hereditary hearing loss APEX microarray (Asper
Biotech, Estonia) contained 198 sequence variants in eight
genes (GJB2, GJB6, GJB3, GJA1, SLC26A4, SLC26A5,
MTRNR1, and MTTS1) associated with, mostly, non-
syndromic SNHL. These microarrays were used and
analyzed as previously described [39].
Exome sequencing and SNP/indel calling
Exome capture and library preparation was performed
using the Agilent SureSelectXT HumanAllExon V4
(50 Mb, product No. 5190–4631). Briefly, 3 μg of gDNA
was sheared to a peak size of 150–200 bp using Covaris.
Fragmented DNA was cleaned with AmpPure XP beads
to remove fragments < 100 bp. The purified DNA frag-
ments were then end-repaired, A-tailed and ligated to
indexing-specific paired-end adaptor using the Agilent
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manufacturer’s instructions.
The adaptor-ligated libraries were amplified for five
cycles with the SureSelect Primer and the SureSelect
Indexing Pre-Capture reverse primer. PCR reactions
were cleaned using the Agencourt AMPure XP. To
capture exonic regions, 500 ng of each prepared library
was hybridized to biotinylated cRNA oligonucleotides
for 24 hours at 65°C. The captured libraries were pulled
down using Dynabeads MyOne Streptavidin T1. A post
capture PCR was then performed to amplify the cap-
tured libraries and to add the barcode sequences for
multiplex sequencing for 14 cycles. Amplified libraries
were purified with AmpPure XP beads. Qubit fluorometer
and Bioanalyzer high sensitivity chips were used to deter-
mine the final concentration of each captured library. One
library was prepared per sample. Libraries were pooled in
pairs, and each pair of libraries was paired-end sequenced
on a single Illumina HiSeq lane at the Stanford Center for
Genomics and Personalized Medicine according to stand-
ard protocols.
Raw fastq files were aligned to hg19, and SNPs and
indels were called using two separate pipelines. Fastq
files were aligned to the hg19 using DNAnexus mapper
with default settings and variants were called using the
DNAnexus Nucleotide-level Variation tool. In addition,
sequence data from the family pedigrees were aligned to
the human reference (hg19 with decoys) and variant
identification was performed with the RTG Variant 1.0
software (commercially available from Real Time Gen-
omics, San Bruno, CA). This software includes a read
hash-table based alignment step with base recalibration,
and a Bayesian variant caller that performs simultaneous
multi-sample scoring for pedigrees and uses priors for
Mendelian variant segregation ([40]; see Additional file 3
for more details). Sex chromosomes are handled as
special cases, and offspring genotypes are phased by
transmission.
Variant filtering
Variants called in the individual probands by DNAnexus
were filtered using Ingenuity Variant Analysis as follows.
Variants with a call quality of at least 20.0 were kept.
Then variants that were observed with an allele fre-
quency ≥ 15.0% of the genomes in the 1000 genomes
project (v3), or ≥ 15.0% of the public Complete Genom-
ics genomes (11/2011), or ≥ 15.0% of the NHLBI ESP
exomes (All) were excluded. Then variants that were ex-
perimentally observed to be associated with a phenotype:
Pathogenic, Possibly Pathogenic, Unknown Significance,
or established gain of function in the literature, or gene
fusions, or inferred activating mutations by Ingenuity, or
predicted gain of function by BSIFT, or in a microRNA
binding site, or Frameshift, in-frame indel, or stop codonchange, or Missense, or disrupt splice site up to 2.0 bases
into intron, or deleterious to a microRNA, or structural
variant were kept. The Ingenuity Variant Analysis version
used was 2.1.20130711. The content versions used were:
Ingenuity Knowledge Base (Xiphias _130613.000), COS-
MIC (v64), dbSNP (Build 137), 1000 Genome Frequency
(v3), TargetScan (v6.2), EVS (ESP6500 0.0.19), JASPAR
(10/12/2009), PhyloP hg18 (11/2009), PhyloP hg19 (01/
2009), Vista Enhancer hg18 (10/27/2007), Vista Enhancer
hg19 (12/26/2010), CGI Genomes (11/2011), SIFT (01/
2013), BSIFT (01/2013), TCGA (5/14/2012), PolyPhen-2
(HumVar Training set 2011_12), Clinvar (4/8/2013). We
also removed variants lying in genes that have emerged as
hyper-variable in published exome-sequencing studies in
some analyses. The variant filtering scheme for each fam-
ily and the isolated cases were slightly different. These dif-
ferences are discussed with the results for each sample set.
Of note, for the family analysis a threshold of 3.0% rather
than 15.0% frequency in the public genomes in order to
study the rarest deleterious mutations segregating in the
families.
Sanger sequencing validation of MYH7B variants
Sequences surrounding the two missense mutations (v1
and v2) were amplified by PCR using the Finzymes Phu-
sion High-Fidelity PCR Master Mix (Thermo Scientific)
and the following forward (F) and reverse (R) primers:
v1F - 5’ CGG CTC AAG AAG AAG ATG GA
v1R - 5’ CCT GCT CGT GGA GCT CAG
v2F - 5’ GCA GTT CTT CAA CCA GCA CA
v2R - 5’ACA CCC TCC CTT CCT CAA AG
PCR cycling was carried out using an optimized ver-
sion of the manufacturer’s protocol involving 35 cycles
with a 30 s annealing step at 65°C and a 10 s elongation
step at 72°C. The PCR products were purified using gel
electrophoresis followed by extraction using a Qiagen
MinElute Gel Extraction kit. The purified products were
sent to Elim Biopharmaceuticals (Hayward, CA, U.S.A.)
for Sanger sequencing using the following sequencing
primers.
v1 - 5’ATG GAG GGT GAC CTC AAC GA
v2 - 5’ TTC CTC AAA GTG ACC TTG CC
The chromatograms were visualized using a demo
version of the Sequencher 5.1 (build 10625) software.
Genome-wide copy number analysis
CNVs were mapped genome-wide to hg18 in all samples
by aCGH using the NimbleGen 2.1 M CNV array (Roche
NimbleGen) followed by analysis in Nexus Copy Number
6 (Biodiscovery) and NimbleScan 2.6 (Roche NimbleGen).
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dye and genomic DNA from a control pool of seven
female individuals (Promega) was labeled using cy5 dye
according to the NimbleGen CGH protocol. 34 μg of test
and control DNA were mixed together and hybridized to
an array for 60–72 hrs. The arrays were washed using the
NimbleGen Wash kit and scanned using the MS 200
scanner (Roche NimbleGen) in two channels: 532 nm and
635 nm. Images were normalized using NimbleScan 2.6
(NS). Normalized data were used to derive LRRs using
two algorithms: NimbleScan 2.6 segMNT algorithm (de-
fault parameters) and Nexus Copy Number 6.0 Rank Seg-
mentation algorithm (significance threshold = 1.0−9). Data
were loaded into Nexus 6.0 and copy number calls were
generated genome-wide for each sample based on fixed
thresholds for deletions and duplications specified in the
settings.
Quality control
Samples were only included in the subsequent analysis if
their hybridization passed two quality control filters.
The first quality control metric is the mad1.dr score
calculated by the segMNT algorithm in NimbleScan 2.6.
This score is the median absolute deviation of the LRR
difference between consecutive probes along the chromo-
some and is a proxy for the overall noisiness of the
hybridization. Hybridizations obtaining a mad1.dr score
of more than 0.23 are considered by the manufacturer too
noisy to be able to discern true differential hybridization
from background noise. The second quality control filter,
the Robust Variance Sample QC score calculated by
Nexus 6.0, is also a measure of probe noise. The probe-to-
probe variance is calculated but the quality control score
takes into account that a certain percentage of variance
outliers are expected due to CNV breakpoints. The score
is calculated by ordering the magnitudes of the variance
between adjacent probes, and then removing the top and
bottom 3% of values. The Nexus recommendation for an
acceptable Robust Variance Sample QC score is less than
0.15-0.2.
CNV association analysis
Genomic region association CNV association analysis
was carried out using the Comparisons function of
Nexus 6 with the classic option. A Fisher’s Exact Test
was performed to determine if the difference between
the frequencies of a CNV region in the cases and in the
controls is significant. The output of the Comparisons
function is a list of regions meeting a maximum p-value
(max p-value) and frequency difference (differential
threshold) between the case and control groups. These
regions are reported in a table such that each region has
constant frequency. That is, if a contiguous genomicsegment for a given event has different frequencies, the
region is split into multiple regions. The Q-bound value
corrects for multiple testing by performing a False Dis-
covery Rate correction. Regions containing CNVs that
were present at a much larger frequency in the cases
versus the controls and incorporating functionally inter-
esting elements were considered top candidates for asso-
ciation. Regions containing CNVs at significant frequencies
in the cases and at very low frequencies in the controls
were selected for manual examination. Odds ratio (OR)
and confidence interval (CI) calculations were carried out
using MedCalc for Windows, version 12.7.2 (MedCalc
Software, Ostend, Belgium).
Gene association Single genes were tested for associ-
ation using a custom built Perl algorithm. The HG18
coordinates of each RefSeq gene were obtained from
UCSC genome browser tables. An overlap algorithm was
applied to determine which RefSeq IDs including 10 kb
up- and downstream overlapped a CNV call from the
cohort by at least one base pair. Those RefSeq IDs that
did contain overlapping CNVs were subjected to a Fish-
er’s Exact Test to determine whether it was significantly
enriched for overlapping CNVs in the cases versus the
controls.
Pathway association 46 genes known to be associated
with hearing loss[1] were found to be located within 36
biological pathways in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) database. These 36 pathways con-
tain 4,548 RefSeq genes in total. Of these genes, 2,729
were affected by a CNV called in our sample set (i.e.
each of these genes had a minimum of 1 bp overlap with
a CNV call). Each of these 2,729 genes was tested for
association with hearing loss as above. In addition, each
of the 36 pathways was also tested for association. In
each sample a pathway was counted as being affected by
CNVs if at least one of its genes was affected by a CNV.
A Fisher’s Exact Test was used to determine whether
any of the 36 pathways were more significantly affected
by CNVs in the cases than in the controls.
CNV validation
All cases and 28 controls were genotyped on the Illumina
Omni-Quad at Centrillion Biosciences. The data were
analyzed for CNVs using the cnvPartition algorithm of the
Illumina GenomeStudio software suite and CNVision
[41]. These data were visualized in Nexus 6. CNVs of
interest were validated by comparison to CNV calls from
the SNP genotyping data with acceptable overlap.
Sample ethnicity determination
Illumina Omni-Quad SNP data were used to determine
the ethnicities of the cases and to confirm a subset of
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the controls. Specifically, we used the markers on the
Illumina Human Omni1Quad array that belonged to
the Human Genome Diversity Project SNP collection as
input. Sample data were formatted using PLINK (http://
pngu.mgh.harvard.edu/purcell/plink/) [42]. Principle com-
ponent analysis was performed to determine the ethnici-
ties of the samples using EIGENSTRAT [43].
Integrated analysis of CNV and SNV data
Genome-wide CNV and SNV data were overlaid using
custom algorithm and IVA in order to detect genomic
loci harboring multiple types of deleterious variants in
13 probands. The CNV data were mapped from hg18 to




Real time genomics analysis
Reads were aligned with the RTG map algorithm to the
hg19 reference with decoys used by the 1000 Genomes
Project1. RTG map creates a hash table that indexes the
reads and streams the reference sequence to identify
mapping locations. Mapping of paired-end reads is
performed concurrently in a collection window that is
much larger than the library insert size (in this case the
window was 1,000 bp). RTG maps also calculate base
QV recalibration tables, which are needed for variant
calling, and outputs standard BAM format files. The
RTG variant caller uses a Bayesian framework (originally
proposed by Marth et al.2) that estimates diploid geno-
type posterior probabilities per and uses priors for poly-
morphism rates based on the data of the 1000 Genomes
Project1. Platform-specific error rates are modelled as
priors and mapping quality values from the mapper are
incorporated as part of the data. Depth of coverage is
also considered during scoring penalizing variants with
higher-than expected coverage. For this, depth of cover-
age needs to be estimated before variant calling; in the
case of exomes a BED file with the target regions is used
to estimate target depth appropriately. Complex regions
are identified by various criteria, mainly including re-
gions with apparent indels, MNPs, or clusters of SNVs.
A specialized Bayesian caller is used for these regions
(“complex caller”) which iteratively selects pre-existing
single-read alignments in the region as hypothesis, aligns
the rest of the reads to the hypothesis by a probabilistic
Goth algorithm and estimates the posterior probability
of each hypothesis considering diploid indels and MNP
variants. The final call is the hypothesis with the highest
posterior probability and accounts for about 10% of the
total variant calls3. In the case of data from pedigrees,
alignments are evaluated simultaneously across pedigreemembers at every position using a scoring method that
assumes Mendelian variant segregation. Sex chromo-
somes are handed as special cases. This dramatically
reduces Mendelian inconsistencies without filtering of
variants, and improves the genotype qualities (GQ) of
true positives, while decreasing the GQ of probably false
positives (unpublished). In order to evaluate the possibil-
ity of de novo mutations, a small prior is allowed for
such type of events and a specific score is calculated for
the de novo mutation hypothesis and it is included in
the output VCF. In the case of nuclear families, offspring
genotypes are phased by transmission. The output is a
multi-sample VCF conforming to v 4.1 specifications
and includes all variants through the score range (i.e. no
filtering is performed by default).
1. Consortium, T. 1. G. P. et al. An integrated map of
genetic variation from 1,092 human genomes.
Nature 490, 56–65 (2013).
2. Marth, G. T. et al. A general approach to single-
nucleotide polymorphism discovery. Nat. Genet. 23,
452–456 (1999).
3. Reumers, J. et al. Optimized filtering reduces the
error rate in detecting genomic variants by short-
read sequencing. Nature Biotechnology 30, 61–68
(2011).
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